Atb Cormark Cm Downgrades Organigram (TSE:OGI) to Moderate Buy

Organigram (TSE:OGI) was downgraded by investment analysts at Atb Cormark Cm from a “strong-buy” rating to a “moderate buy” rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. They presently have a C$3.25 price objective on the stock, down from their previous price objective of C$3.50. Atb Cormark Cm’s price target points to a potential upside of 86.78% from the company’s current price.

Separately, Canaccord Genuity Group set a C$3.00 target price on Organigram and gave the company a “buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of C$3.13.

Organigram Stock Down 1.1%

OGI stock opened at C$1.74 on Wednesday. The company has a current ratio of 3.36, a quick ratio of 2.62 and a debt-to-equity ratio of 3.07. The firm has a 50-day moving average of C$2.29 and a two-hundred day moving average of C$2.30. Organigram has a 12 month low of C$1.22 and a 12 month high of C$3.09. The company has a market cap of C$235.14 million, a price-to-earnings ratio of 11.30, a PEG ratio of 0.42 and a beta of 1.97.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.